5PSQ-049 Effectiveness and renal safety of taf/ftc/evg/cobi in real clinical practice

BackgroundTenofovir alafenamide (TAF) is a new molecule that is being replaced for TDF, the original formulation of tenofovir (TDF), because of its improved efficacy and safety profile in HIV patients.PurposeTo analyse efficacy and renal safety of TAF/FTC/EVG/cobi antiretroviral therapy (ART) in rea...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A187-A187
Main Authors: Soto, A Alcalá, Pichardo, L Jiménez, Germá, P Gómez, Pérez, A Varas, Moreno, C Puivecino, Ariza, I Marín, Calvo, MT Gómez de Travecedo y
Format: Article
Language:English
Subjects:
Antiretroviral drugs
Clinical medicine
Creatinine
Patients
Proteins
Section 5: Patient safety and quality assurance
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundTenofovir alafenamide (TAF) is a new molecule that is being replaced for TDF, the original formulation of tenofovir (TDF), because of its improved efficacy and safety profile in HIV patients.PurposeTo analyse efficacy and renal safety of TAF/FTC/EVG/cobi antiretroviral therapy (ART) in real clinical practice.Material and methodsRetrospective study including all patients who started treatment with TAF/FTC/EVG/cobi from June 2016 to May 2017. Patients were divided into two subgroups: naive and pretreated with other ARTs patients. To determine effectiveness, plasma-HIV RNA (viral load) and CD4-T-lymphocyte (CD4) cell count were measured, and to analyse renal safety, glomerular filtration rate (GFR) and urinary protein to creatinine ratio were measured at baseline and after 6 months’ treatment. Viral load
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2018-eahpconf.403